Ultragenyx Pharmaceutical Inc.
CIK 1515673 · View on SEC EDGAR ↗
Insider
First SEC filing: Oct. 30, 2020 · Latest: Oct. 30, 2020
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 2 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
2 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 11, 2021 | ARCT | S | 75,000 | $45.83 | $3,437,250 | 1,400,000 Direct | -5.08% | Disposed | -74.4% (price as of 2026-08-21) |
| Aug. 10, 2021 | ARCT | S | 725,000 | $55.44 | $40,194,000 | 1,475,000 Direct | -32.95% | Disposed | -78.8% (price as of 2026-08-21) |
| Dec. 9, 2020 | ARCT | S | 357,745 | $94.97 | $33,975,043 | 2,200,000 Direct | -13.99% | Disposed | -87.6% (price as of 2026-08-21) |
| Dec. 8, 2020 | ARCT | S | 442,255 | $105.54 | $46,675,593 | 2,557,745 Direct | -14.74% | Disposed | -88.9% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| May 20, 2020 | ARCT | Option (Right to Buy) | Common Stock (600,000) | $16.00 | June 18, 2021 | 600,000 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.